Despite our improved understanding of pancreatic cancer biology and ability to perform
more complex pancreatic cancer surgeries that produce better short-term outcomes, major …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most common malignant tumors
with poor prognosis due to extremely high malignancy, low rate of eligibility for surgical …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human neoplasms
with extremely poor prognosis and a low survival rate. Immunosuppressive cell populations …

Current cancer treatments may create profound iatrogenic outcomes. The adverse effects of
these treatments still remain, as the serious problems that practicing physicians have to …

Pancreatic ductal adenocarcinoma (PDAC), one of the deadliest malignancies, is resistant to
current chemotherapies. We previously showed that triptolide inhibits PDAC cell growth in …

Pancreatic ductal adenocarcinoma (PAC) stands as the poorest prognostic tumor of the
digestive tract with limited therapeutic options. PAC carcinogenesis is associated with the …

KRAS4B is a highly oncogenic splice variant of the KRAS isoform. It is the only isoform
associated with initiation of adenocarcinomas. Insight into why and how KRAS4B can …

Aims The hedgehog signaling pathway plays an important role in EMT of pancreatic cancer
cells, but the precise mechanisms remain elusive. Because S100A4 as a key EMT moleculer …

Lack of durable response to cytotoxic chemotherapy is a major contributor to the dismal
outcomes seen in pancreatic ductal adenocarcinoma (PDAC). Extensive tumor desmoplasia …

Pancreatic cancer (PC) is an aggressive disease with high mortality rates, however, there is
no blood test for early detection and diagnosis of this disease. Several research groups …